Cargando…
Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia
BACKGROUND: Group 3 pulmonary hypertension (PH) encompasses PH owing to lung diseases and/or hypoxia. Treatment patterns, healthcare resource use, and economic burden to US payers of Group 3 PH patients were assessed. METHODS: This retrospective observational study extracted data from July 1, 2010 t...
Autores principales: | Heresi, Gustavo A., Platt, David M., Wang, Wenyi, Divers, Christine H., Joish, Vijay N., Teal, Simon A., Yu, Justin S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5387228/ https://www.ncbi.nlm.nih.gov/pubmed/28399914 http://dx.doi.org/10.1186/s12890-017-0399-1 |
Ejemplares similares
-
COVID-19 and Pulmonary Arterial Hypertension: Early Data and Many
Questions
por: Farha, Samar, et al.
Publicado: (2020) -
A Case of Fulminant Right Heart Failure Owing to Tumoral Pulmonary Hypertension
por: Wang, Kedong, et al.
Publicado: (2023) -
Mimickers of chronic thromboembolic pulmonary hypertension on imaging
tests: a review
por: Narechania, Shraddha, et al.
Publicado: (2020) -
Use of Sildenafil in Pulmonary Arterial Hypertension: Findings from a U.S. Healthcare Claims Database
por: Berger, Ariel, et al.
Publicado: (2014) -
Assessment for residual disease after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension
por: Butler, Oisín, et al.
Publicado: (2022)